Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

ConclusionMild RI and HI do not necessitate fedratinib dosage adjustments. Subjects with moderate RI should be monitored (with dosage adjustments made as necessary), whereas those with severe RI should receive a daily dose of 200  mg, reduced from the indicated dose of 400 mg.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research